Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
IFM Therapeutics, LLC Appoints World-Renowned Physicians and Researchers to Clinical Advisory Board | ||
By: PR Newswire Association LLC. - 20 Jun 2018 | Back to overview list |
|
BOSTON, June 20, 2018 /PRNewswire-USNewswire/ -- IFM Therapeutics, LLC (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system to treat inflammatory disorders and cancer, today announced the appointment of eight distinguished physician-scientists in inflammation research to its clinical advisory board (CAB). These CAB members represent a broad range of research disciplines, from neurodegeneration to metabolic disorders, brought together by their profound expertise on the role inflammation plays in the progression of these diseases. The experience and guidance of the CAB will be instrumental as IFM advances its current research programs into clinical development and expands its pipeline of novel inhibitors. New IFM CAB appointees are:
"We are thrilled to welcome this accomplished and distinguished group of clinical and inflammation experts to IFM's clinical advisory board," said H. Martin Seidel, executive vice president of R&D. "The new CAB appointees represent IFM Therapeutics, LLC's current focus on inflammation targets following the company's sale of its former immuno-oncology programs in 2017. The new members are dedicated to expanding our understanding of the innate immune system and bringing patients with inflammatory diseases better treatment options. We look forward to gaining important insights from this renowned group of experts." The new IFM Therapeutics, LLC clinical advisory board appointees will join existing members Dr. Michael Heneka, Dr. Hal Hoffman, and Dr. Saurabh Saha. About IFM Therapeutics, LLC IFM Therapeutics, LLC is a privately held biopharmaceutical company based in Boston, Massachusetts. The company was founded by an international group of preeminent scientists and physicians who have spent decades understanding innate immunity and the role it plays in regulating the immune system. IFM's team has discovered and developed small molecules that modulate novel targets in the innate immune system as next-generation therapies for cancer, autoimmunity, and inflammatory disorders. For more information, please visit www.ifmthera.com. View original content with multimedia:http://www.prnewswire.com/news-releases/ifm-therapeutics-llc-appoints-world-renowned-physicians-and-researchers-to-clinical-advisory-board-300668948.html SOURCE IFM Therapeutics |
||
|
||
Copyright 2018 PR Newswire Association LLC. | Back to overview list |